Skip to main content

Pre-clinical improvement of combined immunotherapy and chemotherapy for a new variant Creutzfeldt-Jakob disease

Objective

Tees are invariably fatal and are still incurable. Recent reports have shown that anti-Prepuce antibodies reduce Prep’s in infected-infected cells. Based on this data, we have infused anti-Prep antibody Fib fragments intracerebroventricularly in FVB mice with experimental scrape and demonstrated a delay in the clinical signs. The aims of this project are:
(i) to confirm these encouraging results in mice with experimental scrape or BSE,
(ii) to optimise immunotherapy protocols (intracerebroventricular and intraperitoneal),
(iii) to combine this immunotherapy with emerging chemotherapeutic agents including the chlorpromazine/aquamarine regimen, and
(iv) to rationally improve the anti-Prep antibodies, by creating chimerical constructs with targeted transcytosis through the blood/brain endothelium. These studies will culminate in phase I clinical trials in human niche and CJD patients.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

THE NETHERLANDS CANCER INSTITUTE / ANTONI VAN LEEUWENHOEK HOSPITAL
Address
121,Plesmanlaan 121
1066 CX Amsterdam
Netherlands

Participants (3)

CLB - SANQUIN BLOOD SUPPLY FOUNDATION
Netherlands
Address
Plesmanlaan 125
1066 CX Amsterdam
KAROLINSKA INSTITUTE
Sweden
Address
Retzius Vaeg 8
171 77 Stockholm
UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II
Italy
Address
Via Sergio Pansini 5
80131 Napoli